Block Grant R43AI077225

This $138,189 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop a glioblastoma stem cell (GSC) vaccine for the prevention and control of the aggressive and incurable brain cancer glioblastoma (GBM). The research, conducted by North Carolina Agricultural and Technical State University, aims to assess the vaccine's...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $639,004 to Mayo Clinic from January 1, 2025 to December 31, 2029 to conduct research on using a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key products and services to be delivered under this award include: Collecting and processing pre- and post-treatment tumor tissue and peripheral blood samples...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Northwestern University provides $577,634 to investigate the role of the SEC61 protein complex in overcoming resistance to immunotherapy in glioblastoma (GBM), an aggressive form of brain cancer. The key objectives are to: 1) understand how SEC61G expression interacts with the MAPK pathway to contribute to T cell-mediated therapeutic resistance in glioma cells; 2) determine the impact of...

This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...

This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...

The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...

This federal Project Grant award of $417,858 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) is funding the development of novel engineered mesenchymal stem cell (MSC) therapies that release bi-specific T cell engagers (BiTEs) to target brain tumors called glioblastomas (GBMs). The key products and services to be delivered under this 5-year grant include: 1) Engineering MSCs to...

This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research on targeted radioimmunotherapy for glioblastoma, a highly aggressive form of brain cancer. The $432,134 award was granted on June 5, 2025 to the University of Texas MD Anderson Cancer Center. The research aims to develop an innovative treatment approach using IL13RA2, a cell surface receptor expressed on glioblastoma tumors, as a target for delivering cytotoxic radioisotopes....